556 related articles for article (PubMed ID: 19119142)
1. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
[TBL] [Abstract][Full Text] [Related]
2. De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells.
Berdyshev EV; Gorshkova IA; Usatyuk P; Zhao Y; Saatian B; Hubbard W; Natarajan V
Cell Signal; 2006 Oct; 18(10):1779-92. PubMed ID: 16529909
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.
Diab KJ; Adamowicz JJ; Kamocki K; Rush NI; Garrison J; Gu Y; Schweitzer KS; Skobeleva A; Rajashekhar G; Hubbard WC; Berdyshev EV; Petrache I
Am J Respir Crit Care Med; 2010 Feb; 181(4):344-52. PubMed ID: 19965812
[TBL] [Abstract][Full Text] [Related]
4. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.
Lahiri S; Park H; Laviad EL; Lu X; Bittman R; Futerman AH
J Biol Chem; 2009 Jun; 284(24):16090-16098. PubMed ID: 19357080
[TBL] [Abstract][Full Text] [Related]
5. Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1.
Zhao Y; Kalari SK; Usatyuk PV; Gorshkova I; He D; Watkins T; Brindley DN; Sun C; Bittman R; Garcia JG; Berdyshev EV; Natarajan V
J Biol Chem; 2007 May; 282(19):14165-77. PubMed ID: 17379599
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Butler J; Lana D; Round O; LaMontagne K
Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.
Billich A; Bornancin F; Dévay P; Mechtcheriakova D; Urtz N; Baumruker T
J Biol Chem; 2003 Nov; 278(48):47408-15. PubMed ID: 13129923
[TBL] [Abstract][Full Text] [Related]
8. FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl.
Wang L; Chiang ET; Simmons JT; Garcia JG; Dudek SM
Eur Respir J; 2011 Jul; 38(1):78-88. PubMed ID: 21071472
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
[TBL] [Abstract][Full Text] [Related]
10. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.
Sarai K; Shikata K; Shikata Y; Omori K; Watanabe N; Sasaki M; Nishishita S; Wada J; Goda N; Kataoka N; Makino H
Am J Physiol Cell Physiol; 2009 Oct; 297(4):C945-54. PubMed ID: 19657053
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
Zemann B; Kinzel B; Müller M; Reuschel R; Mechtcheriakova D; Urtz N; Bornancin F; Baumruker T; Billich A
Blood; 2006 Feb; 107(4):1454-8. PubMed ID: 16223773
[TBL] [Abstract][Full Text] [Related]
12. FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.
Vessey DA; Li L; Imhof I; Honbo N; Karliner JS
Med Sci Monit Basic Res; 2013 Apr; 19():126-32. PubMed ID: 23567658
[TBL] [Abstract][Full Text] [Related]
13. Photolysis of caged sphingosine-1-phosphate induces barrier enhancement and intracellular activation of lung endothelial cell signaling pathways.
Usatyuk PV; He D; Bindokas V; Gorshkova IA; Berdyshev EV; Garcia JG; Natarajan V
Am J Physiol Lung Cell Mol Physiol; 2011 Jun; 300(6):L840-50. PubMed ID: 21478254
[TBL] [Abstract][Full Text] [Related]
14. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
15. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
16. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
Paugh SW; Payne SG; Barbour SE; Milstien S; Spiegel S
FEBS Lett; 2003 Nov; 554(1-2):189-93. PubMed ID: 14596938
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Sanchez T; Estrada-Hernandez T; Paik JH; Wu MT; Venkataraman K; Brinkmann V; Claffey K; Hla T
J Biol Chem; 2003 Nov; 278(47):47281-90. PubMed ID: 12954648
[TBL] [Abstract][Full Text] [Related]
19. Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
Huwiler A; Pfeilschifter J
Curr Pharm Des; 2006; 12(35):4625-35. PubMed ID: 17168766
[TBL] [Abstract][Full Text] [Related]
20. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Li MH; Hla T; Ferrer F
Pediatr Blood Cancer; 2013 Sep; 60(9):1418-23. PubMed ID: 23704073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
